Physician profile
Mayelin Gonzalez Alonso
NPI 1750745733
$2,543.80
in general payments reported to CMS, 2019-2025
22 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $234 · 2024: $939 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $496.80 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $302.63 | 2023-2025 | Ultomiris |
| Abbvie INC. | $250.78 | 2023-2025 | |
| Ucb, INC. | $234.74 | 2023-2025 | Rystiggo, Nayzilam, Zilbrysq |
| Otsuka America Pharmaceutical, INC. | $222.21 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $213.61 | 2024-2025 | |
| Pfizer INC. | $125.26 | 2024-2025 | |
| Lilly USA, LLC | $104.74 | 2023-2025 | Emgality, Amyvid, Kisunla |
| Janssen Biotech, INC. | $83.06 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $62.75 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $61.70 | 2024-2025 | Rexulti |
| Dexcom, INC. | $50.64 | 2024 | Dexcom G6 Transmitter |
| Emd Serono, INC. | $49.89 | 2023-2024 | Mavenclad |
| Sumitomo Pharma America, INC. | $49.56 | 2023-2024 | Aptiom |
| Amneal Pharmaceuticals LLC | $39.88 | 2025 | Ongentys, Crexont |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $38.58 | 2023 | |
| Genentech USA, INC. | $38.46 | 2025 | Actemra, Ocrevus Zunovo |
| Axsome Therapeutics, INC. | $28.82 | 2025 | Symbravo |
| Aucta Pharmaceuticals, INC. | $27.11 | 2025 | Motpoly Xr |
| Abbott Laboratories | $27.05 | 2024 | Cardiomems |
| Acadia Pharmaceuticals INC | $18.62 | 2024 | Nuplazid |
| Biogen, INC. | $16.91 | 2024 | Avonex, Vumerity, Tysabri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayelin Gonzalez Alonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.